South Korea-based SK Biopharmaceuticals has collaborated with an artificial intelligence-driven biopharmaceutical firm, twoXAR, for the discovery and development of products to treat non-small cell lung cancer, it was reported yesterday.
According to the terms of the deal, twoXAR will implement its AI discovery technology to identify a set of initial candidates to treat lung cancer through novel biological mechanisms of action. Upon completion of screening, SK Biopharmaceuticals will use its internal AI Drug Design technology to advance a lead candidate and then carry out IND-enabling studies.
SK will hold exclusive worldwide rights for the development and commercialisation of any drug candidate. twoXAR will received an upfront payment and will receive development and commercial milestone payments and royalties.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval